ERBC (ex CERB) has acquired RTC
The European Research Biology Center (ERBC) has acquired the Research Toxicology Center (RTC).
ERBC provides healthcare and chemical professionals a comprehensive range of experimental capabilities and services, from preclinical proof-of-concept to market of any type of drug candidate or chemical compound. Each project is managed by a study director, relying on a multi-disciplinary team of experts, notably in general pharmacology, cardiology, electrophysiology and pathophysiology, and also benefiting from a world-class academic and private network.
RTC is a fully fledged contract research laboratory located near Rome, Italy, with a track record spanning more than four decades. RTC collaborates with a large range of industrial clients including the pharmaceutical, biotech, chemical, agro-chemical and biocide industries.
Oaklins' team in France advised the buyer in this transaction.



Serge Richard
CEO, ERBC
Talk to the deal team

Related deals
Seniovo GmbH has been acquired by HORNBACH Baumarkt AG
The shareholders of Seniovo GmbH have sold the company to HORNBACH Baumarkt AG.
Learn moreNordian Capital has raised debt to acquire Wetac
Nordian Capital, a Netherlands-based private equity firm, has joined the shareholder base of Wetac Battery Company (Wetac), a leading supplier of batteries, battery systems and accessories for various applications and end markets. The financing was provided by OLB and will support Wetac’s strong growth ambitions.
Learn moreNordian joins the shareholder base of Wetac to support further growth
Nordian, a Netherlands-based private equity firm, has joined the shareholder base of Wetac, a leading supplier of batteries and battery systems for various applications and end markets.
Learn more